Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ampreloxetine - Theravance Biopharma

Drug Profile

Ampreloxetine - Theravance Biopharma

Alternative Names: Ampreloxetine; TD-9855

Latest Information Update: 11 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theravance
  • Developer Theravance Biopharma
  • Class Analgesics; Antihypotensives; Piperidines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Orthostatic hypotension
  • No development reported Fibromyalgia
  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 25 Jan 2019 Theravance Biopharma plans a phase III trial for symptomatic neurogenic Orthostatic hypotension (nOH) in January 2019 (PO) (NCT03829657)
  • 08 Jan 2019 Phase-III clinical trials in Orthostatic hypotension in USA (PO) (NCT03750552)
  • 14 Aug 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top